Since the pandemic, remote medical consultations have become a routine part of healthcare provision. But the concept of remote consultations mediated via communication technology is not as new as we might expect, and was in fact predicted a century ago.
{"title":"Remote consultations: a prescription from the past?","authors":"B. Caddick","doi":"10.1002/psb.2054","DOIUrl":"https://doi.org/10.1002/psb.2054","url":null,"abstract":"Since the pandemic, remote medical consultations have become a routine part of healthcare provision. But the concept of remote consultations mediated via communication technology is not as new as we might expect, and was in fact predicted a century ago.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"88 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77251727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ongoing research into the use of messenger RNA (mRNA) vaccines for the treatment of cancer has been expediated by the coronavirus pandemic because similar technology was used in the development of mRNA COVID‐19 vaccines. So how close are we now to the widespread clinical use of mRNA anti‐cancer vaccines?
{"title":"mRNA anti‐cancer vaccine research gains momentum","authors":"M. Greener","doi":"10.1002/psb.2047","DOIUrl":"https://doi.org/10.1002/psb.2047","url":null,"abstract":"Ongoing research into the use of messenger RNA (mRNA) vaccines for the treatment of cancer has been expediated by the coronavirus pandemic because similar technology was used in the development of mRNA COVID‐19 vaccines. So how close are we now to the widespread clinical use of mRNA anti‐cancer vaccines?","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"116 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81083852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The Scottish Intercollegiate Guidelines Network (SIGN) has recently updated its guideline on the pharmacological management of migraine (SIGN 155) to include new information on the use of anti‐CGRP monoclonal antibodies. This article provides a round‐up of the main changes to the guidance.
{"title":"SIGN updates its guideline on the management of migraine","authors":"S. Chaplin","doi":"10.1002/psb.2048","DOIUrl":"https://doi.org/10.1002/psb.2048","url":null,"abstract":"The Scottish Intercollegiate Guidelines Network (SIGN) has recently updated its guideline on the pharmacological management of migraine (SIGN 155) to include new information on the use of anti‐CGRP monoclonal antibodies. This article provides a round‐up of the main changes to the guidance.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72744790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tezepelumab (Tezspire) is a new monoclonal antibody therapy for add‐on treatment in adolescents and adults with inadequately controlled severe asthma. This article outlines its mode of action, indication and clinical trial outcomes.
{"title":"Tezepelumab as add‐on treatment for severe asthma","authors":"S. Chaplin","doi":"10.1002/psb.2050","DOIUrl":"https://doi.org/10.1002/psb.2050","url":null,"abstract":"Tezepelumab (Tezspire) is a new monoclonal antibody therapy for add‐on treatment in adolescents and adults with inadequately controlled severe asthma. This article outlines its mode of action, indication and clinical trial outcomes.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87905942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Medicalising normal life has its risks","authors":"","doi":"10.1002/psb.2038","DOIUrl":"https://doi.org/10.1002/psb.2038","url":null,"abstract":"","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"103 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77733644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tuberculosis is treated mainly in secondary care, but patients commonly present to primary care for investigation of initial symptoms and treatment monitoring. This article discusses the most frequently used anti‐tuberculosis drugs, their monitoring requirements and how to manage drug interactions and adverse reactions.
{"title":"Managing patients with tuberculosis in primary care","authors":"A. Chavda, T. Capstick, O. Kon","doi":"10.1002/psb.2039","DOIUrl":"https://doi.org/10.1002/psb.2039","url":null,"abstract":"Tuberculosis is treated mainly in secondary care, but patients commonly present to primary care for investigation of initial symptoms and treatment monitoring. This article discusses the most frequently used anti‐tuberculosis drugs, their monitoring requirements and how to manage drug interactions and adverse reactions.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77183450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
NICE has recently published an update of its guidance on the diagnosis and non‐surgical management of osteoarthritis. This article provides a summary of the new guidance, which focuses on the benefits of therapeutic exercise for people with osteoarthritis.
{"title":"NICE on the diagnosis and management of osteoarthritis","authors":"S. Chaplin","doi":"10.1002/psb.2040","DOIUrl":"https://doi.org/10.1002/psb.2040","url":null,"abstract":"NICE has recently published an update of its guidance on the diagnosis and non‐surgical management of osteoarthritis. This article provides a summary of the new guidance, which focuses on the benefits of therapeutic exercise for people with osteoarthritis.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72655893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：